ArticleProceedings of the National Academy of Sciences of the United States of America2010
Peptide antagonism as a mechanism for NK cell activation.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 159 citations in OpenAlex.
- IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion.The Journal of clinical investigation · 2014Trial
- Protein language models accurately predict polymorphic peptide-modulated NK cell receptor-HLA class I interaction strengths.Science advances · 2026Article
- Development and evaluation of an inhalable nanoemulsion system for enhancing NK cell function against osteosarcoma pulmonary metastases.Frontiers in immunology · 2026Article
- Peptide-specific natural killer cell receptors.Oxford open immunology · 2025Review
- Article
- Emerging mutation in SARS-CoV-2 facilitates escape from NK cell recognition and associates with enhanced viral fitness.PLoS pathogens · 2024Article
- The nuclear export protein XPO1 provides a peptide ligand for natural killer cells.Science advances · 2024Article
- CRISPR-Cas9 screening reveals a distinct class of MHC-I binders with precise HLA-peptide recognition.iScience · 2024Article
- Upregulation of the NKG2D Ligand ULBP2 by JC Polyomavirus Infection Promotes Immune Recognition by Natural Killer Cells.The Journal of infectious diseases · 2024Article
- Using In silico models to predict lymphocyte activation and development in a data rich era.Immunoinformatics (Amsterdam, Netherlands) · 2024Article
- The Role of Epigenetic Factors in the Pathogenesis of Psoriasis.International journal of molecular sciences · 2024Review
- Human leukocyte antigen system associations in Malassezia-related skin diseases.Archives of dermatological research · 2023Article
- NK cell education: Physiological and pathological influences.Frontiers in immunology · 2023Review
- KIR-HLA gene diversities and susceptibility to lung cancer.Scientific reports · 2022Article
- Fine-mapping studies distinguish genetic risks for childhood- and adult-onset asthma in the HLA region.Genome medicine · 2022Article
- HLA-B*57:01 Complexed to a CD8 T-Cell Epitope from the HSV-2 ICP22 Protein Binds NK and T Cells through KIR3DL1.Viruses · 2022Article
- Association between HLA-C alleles and COVID-19 severity in a pilot study with a Spanish Mediterranean Caucasian cohort.PloS one · 2022Article
- Neoantigens and NK Cells: "Trick or Treat" the Cancers?Frontiers in immunology · 2022Review
- The New Kid on the Block: HLA-C, a Key Regulator of Natural Killer Cells in Viral Immunity.Cells · 2021Review
- Exploring peptide studies related to SARS-CoV to accelerate the development of novel therapeutic and prophylactic solutions against COVID-19.Journal of infection and public health · 2021Review
42 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
Inhibition of natural killer (NK) cells is mediated by MHC class I receptors including the killer cell Ig-like receptor (KIR). We demonstrate that HLA-C binding peptides can function as altered peptide ligands for KIR and antagonize the inhibition mediated by KIR2DL2/KIR2DL3. Antagonistic peptides promote clustering of KIR at the interface of effector and target cells, but do not result in inhibition of NK cells. Our data show that, as for T cells, small changes in the peptide content of MHC class I can regulate NK cell activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.